Comprehensive Genomic Profiling Identifies a Subset of Crizotinib-Responsive ALK-Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In Situ Hybridization

INTRODUCTION. For patients with non-small cell lung cancer (NSCLC) to benefit from ALK inhibitors, sensitive and specific detection of ALK genomic rearrangements is needed. ALK break-apart fluorescence in situ hybridization (FISH) is the U.S. Food and Drug Administration approved and standard-of-car...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncologist
Main Authors: Ali, Siraj M., Hensing, Thomas, Schrock, Alexa B., Allen, Justin, Sanford, Eric, Gowen, Kyle, Kulkarni, Atul, He, Jie, Suh, James H., Lipson, Doron, Elvin, Julia A., Yelensky, Roman, Chalmers, Zachary, Chmielecki, Juliann, Peled, Nir, Klempner, Samuel J., Firozvi, Kashif, Frampton, Garrett M., Molina, Julian R., Menon, Smitha, Brahmer, Julie R., MacMahon, Heber, Nowak, Jan, Ou, Sai-Hong Ignatius, Zauderer, Marjorie, Ladanyi, Marc, Zakowski, Maureen, Fischbach, Neil, Ross, Jeffrey S., Stephens, Phil J., Miller, Vincent A., Wakelee, Heather, Ganesan, Shridar, Salgia, Ravi
Formato: Artigo
Idioma:Inglês
Publicado em: AlphaMed Press 2016
Assuntos:
Lung Cancer
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4912370/
https://ncbi.nlm.nih.gov/pubmed/27245569
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2015-0497
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados